BeyondSpring (BYSI) Liabilities from Discontinued Operations (2023 - 2026)
BeyondSpring (BYSI) posted Liabilities from Discontinued Operations of 9263000.0 for Q1 2026, down 16.8% sequentially from 11133000.0 in Q4 2025, and down 4.83% YoY from 9733000.0 in Q1 2025.
BeyondSpring (BYSI) Liabilities from Discontinued Operations (2023 - 2026) Analysis & Trends
BeyondSpring has reported Liabilities from Discontinued Operations for 4 years, with the latest figure at 9263000.0 in Q1 2026.
- Quarterly Liabilities from Discontinued Operations fell 4.83% year-over-year to 9263000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 9263000.0 (down 4.83% YoY) and the FY2025 annual result came in at 11133000.0, up 26.32% from the prior year.
- Liabilities from Discontinued Operations declined to 9263000.0 in Q1 2026 per BYSI's latest filing, from 11133000.0 in the prior quarter.
- Over five years, Liabilities from Discontinued Operations peaked at 11133000.0 in Q4 2025 and troughed at 7847000.0 in Q4 2023.
- A 4-year average of 9573714.29 and a median of 9619000.0 in 2025 frame the typical range for Liabilities from Discontinued Operations.
- The sharpest annual moves came in 2025 and 2026: Liabilities from Discontinued Operations increased 26.32% in 2025, then dropped 4.83% in 2026.
- Over 4 years, Liabilities from Discontinued Operations stood at 7847000.0 in 2023, then grew by 12.31% to 8813000.0 in 2024, then increased by 26.32% to 11133000.0 in 2025, then fell by 16.8% to 9263000.0 in 2026.
- According to Business Quant data, Liabilities from Discontinued Operations over the past three periods registered 9263000.0, 11133000.0, and 10608000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | BeyondSpring | 29.85 Mn | 29.85 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.79 Mn |
| Jun 30, 2026 | 10.79 Mn |
| Mar 31, 2026 | 9.26 Mn |
| Mar 31, 2026 | 9.26 Mn |
| Dec 31, 2025 | 11.13 Mn |
| Dec 31, 2025 | 11.13 Mn |
| Sep 30, 2025 | 10.61 Mn |
| Sep 30, 2025 | 10.61 Mn |
| Jun 30, 2025 | 9.62 Mn |
| Jun 30, 2025 | 9.62 Mn |
| Mar 31, 2025 | 9.73 Mn |
| Mar 31, 2025 | 9.73 Mn |
| Dec 31, 2024 | 8.81 Mn |
| Dec 31, 2024 | 8.81 Mn |
| Dec 31, 2023 | 7.85 Mn |
| Dec 31, 2023 | 7.85 Mn |